RxDoctor Payments Data

Rakesh Parikh, MD

Family Medicine · Merrillville, INNPI 1922072503

Payments from drug & device makers

$4,370in general payments, 2019–2025

Across 196 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$483
  • Merck$440
  • Amgen$393
  • AstraZeneca$338
  • AbbVie$232
  • Galderma Laboratories, L.p.$226
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,359100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,370 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$282,611
Medicare patients
256
Services billed
3,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$94,646
XifaxanRifaximin38$59,048
OzempicSemaglutide41$57,590
JardianceEmpagliflozin59$41,837
TradjentaLinagliptin50$35,636
EntrestoSacubitril/Valsartan90$32,913
LinzessLinaclotide45$27,009
XareltoRivaroxaban69$25,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$19,072
MounjaroTirzepatide13$13,165
BrilintaTicagrelor25$11,429
FarxigaDapagliflozin Propanediol16$10,799
Sevelamer Hcl14$10,198
NamzaricMemantine Hcl/Donepezil Hcl26$7,710
AbrysvoRsv Vacc, Pref A And Pref B/Pf21$6,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$148$101,260286 claims
Boehringer IngelheimJardiance, Tradjenta$137$77,473109 claims
Novo NordiskOzempic$14$57,59041 claims
AbbVieLinzess, Namzaric$232$34,71971 claims
NovartisEntresto$483$32,91390 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$74$29,64163 claims
AstraZenecaBrilinta, Farxiga, Lokelma$338$28,38354 claims
Johnson & JohnsonXarelto$17$25,54169 claims
Lilly USA, LLCMounjaro$37$13,16513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →